Cognizant: Solid Execution, Strong Bookings, and Strategic AI Positioning Underpin Buy Rating

William Blair analyst Maggie Nolan has maintained their bullish stance on CTSH stock, giving a Buy rating yesterday.

Maggie Nolan has given his Buy rating due to a combination of factors that highlight Cognizant’s solid execution and favorable outlook. The company delivered fourth-quarter results that surpassed market expectations on revenue and margins, and its initial 2026 guidance calls for better-than-consensus revenue growth and operating profitability. Revenue is growing organically, led by North America and financial services, and management expects this organic growth to continue at a modest but steady pace, complemented by additional contribution from acquisitions. At the same time, book-to-bill trends are strong: bookings rose at a healthy clip, supported by record total contract value and a substantial increase in very large deals, indicating solid demand and improved deal quality.

Nolan also points to business mix and strategic positioning as key supports for the Buy rating. The rising share of fixed-price and outcome-based contracts—now about half of revenue—underscores Cognizant’s ability to manage risk and maintain margins while clients increasingly focus on measurable value. In health sciences, which accounts for a sizeable portion of revenue, regulatory and payer uncertainty is creating additional demand for platforms like TriZetto that help reduce administrative costs and streamline claims. Furthermore, Cognizant is advancing its AI strategy with thousands of AI projects already executed and a growing portion of development work leveraging AI tools, which should enhance productivity and competitiveness over time. Although enterprise spending remains somewhat fluid, especially in discretionary IT budgets, Nolan sees improving signals in core verticals such as financial services and healthcare that reinforce the positive investment case.

In another report released yesterday, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $82.00 price target.